Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cognition researchers Cogstate has licensed its technology to Japanese pharmaceutical company Eisai
  • The company will initially receive US$1 million in royalty fees
  • Cogstate’s share price is up 7.69 per cent today, currently sitting at $0.21 apiece

Cognition researchers Cogstate have licensed its technology to Japanese pharmaceutical company Eisai.

The exclusive agreement will see Eisai promote Cogstate’s technology to the Japanese market as a digital assessment tool for cognition.

Cogstate’s clinical trials will be excluded from the agreement, so the company can continue to self market them.

Eisai will pay US$1 million as an upfront royalty fee and cover any additional development costs to tailor the product for the Japanese market.

CEO at Cogstate Brad O’Connor said: “We are honoured to align with Eisai as they progress their plans to address the unmet needs of patients through innovation… as we continue to work together in the quest for a cure for Alzheimer’s disease.”

Initially, the agreement is set for 10 years, with performance reviews at year five and eight to maintain exclusivity.

Additionally, the company is looking to raise $2.86 million from shareholders, to assist in funding the scientific, operational and technical support of Cogstate’s technology in Japan.

Cogstate’s share price is up 7.69 per cent today, currently sitting at $0.21 apiece, as of AEST 3:42 pm.

CGS by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.